Apolipoprotein L1 and Kidney Disease in African Americans

Trends in Endocrinology and Metabolism

Volumn 27, Issue 4, 2016, Pages 204-215

  Friedman, David J ^a   Pollak, Martin R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

African American; APOL1; Apolipoprotein L1; Kidney disease

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN;

AFRICAN AMERICAN; APOLIPOPROTEIN L1 GENE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GENE; GENETIC VARIABILITY; GENOTYPE; HIV ASSOCIATED NEPHROPATHY; HUMAN; IN VITRO STUDY; KIDNEY DISEASE; KIDNEY GRAFT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAMMAL CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TRANSGENIC ANIMAL; TRYPANOSOMA; AFRICA; AFRICAN TRYPANOSOMIASIS; ANIMAL; BLOOD; DISEASE RESISTANCE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; IMMUNOLOGY; MUTATION;

AFRICA; AFRICAN AMERICANS; ANIMALS; APOLIPOPROTEINS; DISEASE RESISTANCE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; KIDNEY DISEASES; LIPOPROTEINS, HDL; MUTATION; TRYPANOSOMIASIS, AFRICAN;

EID: 84959315811     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.02.002     Document Type: Review

References (82)

1. US Renal Data System Atlas 2009, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
2. Genovese G., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329:841-845.
3. Tzur S., et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 2010, 128:345-350.
4. Page N.M., et al. The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics 2001, 74:71-78.
5. Duchateau P.N., et al. Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J. Lipid Res. 2001, 42:620-630.
6. Smith E.E., Malik H.S. The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res. 2009, 19:850-858.
7. Uhlen M., et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347:1260419.
8. Vanhamme L., et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003, 422:83-87.
9. Friedman D.J., Pollak M.R. Genetics of kidney failure and the evolving story of APOL1. J. Clin. Invest. 2011, 121:3367-3374.
10. Pays E., et al. The trypanolytic factor of human serum. Nat. Rev. Microbiol. 2006, 4:477-486.
11. Tin A., et al. Hemostatic factors, APOL1 risk variants, and the risk of ESRD in the Atherosclerosis Risk in Communities Study. Clin. J. Am. Soc. Nephrol. 2015, 10:784-790.
12. Kopp J.B., et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 2011, 22:2129-2137.
13. Friedman D.J., et al. Population-based risk assessment of APOL1 on renal disease. J. Am. Soc. Nephrol. 2011, 22:2098-2105.
14. Lin C.P., et al. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun. 2012, 13:232-238.
15. Larsen C.P., et al. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J. Am. Soc. Nephrol. 2013, 24:722-725.
16. Freedman B.I., et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014, 66:390-396.
17. Larsen C.P., et al. Histopathologic effect of APOL1 risk alleles in PLA2R-associated membranous glomerulopathy. Am. J. Kidney Dis. 2014, 64:161-163.
18. Parsa A., et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 2013, 369:2183-2196.
19. Freedman B.I., et al. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 2015, 87:176-181.
20. Vanhollebeke B., et al. Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. N. Engl. J. Med. 2006, 355:2752-2756.
21. Johnstone D.B., et al. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS ONE 2012, 7:e51546.
22. Kanji Z., et al. Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J. Am. Soc. Nephrol. 2011, 22:2091-2097.
23. Tzur S., et al. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol. Dial. Transplant. 2012, 27:1498-1505.
24. Bruggeman L.A., et al. Plasma apolipoprotein L1 levels do not correlate with CKD. J. Am. Soc. Nephrol. 2014, 25:634-644.
25. Cheng D., et al. Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells. J. Lipid Res. 2015, 56:1583-1593.
26. Weckerle A., et al. Characterization of circulating APOL1 protein complexes in African Americans. J. Lipid Res. 2016, 57:120-130.
27. Madhavan S.M., et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J. Am. Soc. Nephrol. 2011, 22:2119-2128.
28. Ma L., et al. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J. Am. Soc. Nephrol. 2015, 26:339-348.
29. Reeves-Daniel A.M., et al. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transplant. 2011, 11:1025-1030.
30. Freedman B.I., et al. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am. J. Transplant. 2015, 15:1615-1622.
31. Freedman B.I., et al. APOL1 genotype and kidney transplantation outcomes from deceased African American donors. Transplantation 2015, 100:194-202.
32. Lee B.T., et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am. J. Transplant. 2012, 12:1924-1928.
33. Divers J., et al. Gene-gene interactions in APOL1-associated nephropathy. Nephrol. Dial. Transplant. 2014, 29:587-594.
34. Kasembeli A.N., et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J. Am. Soc. Nephrol. 2015, 26:2882-2890.
35. Markowitz G.S., et al. Treatment with IFN-α, -β, or -γ is associated with collapsing focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2010, 5:607-615.
36. Nichols B., et al. Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int. 2015, 87:332-342.
37. Kimmel P.L., et al. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann. Intern. Med. 2003, 139:214-226.
38. Obermoser G., Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010, 19:1012-1019.
39. Monajemi H., et al. The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue. Genomics 2002, 79:539-546.
40. Wan G., et al. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J. Biol. Chem. 2008, 283:21540-21549.
41. Zhaorigetu S., et al. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 2008, 4:1079-1082.
42. Thomson R., et al. Evolution of the primate trypanolytic factor APOL1. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E2130-E2139.
43. Lan X., et al. Protein domains of APOL1 and its risk variants. Exp. Mol. Pathol. 2015, 99:139-144.
44. Lan X., et al. Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu. Exp. Mol. Pathol. 2015, 98:491-501.
45. Khatua A.K., et al. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1. Am. J. Physiol. Cell Physiol. 2015, 309:C22-C37.
46. Lan X., et al. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am. J. Physiol. Renal Physiol. 2014, 307:F326-F336.
47. Molina-Portela Mdel P., et al. Trypanosome lytic factor, a subclass of high-density lipoprotein, forms cation-selective pores in membranes. Mol. Biochem. Parasitol. 2005, 144:218-226.
48. Perez-Morga D., et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005, 309:469-472.
49. Vanwalleghem G., et al. Coupling of lysosomal and mitochondrial membrane permeabilization in trypanolysis by APOL1. Nat. Commun. 2015, 6:8078.
50. Thomson R., Finkelstein A. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:2894-2899.
51. Olabisi O.A., et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc. Natl. Acad. Sci. U.S.A. 2016, 113:830-837.
52. Marino G., et al. Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2014, 15:81-94.
53. Heneghan J.F., et al. BH3 domain-independent apolipoprotein L1 toxicity rescued by BCL2 prosurvival proteins. Am. J. Physiol. Cell Physiol. 2015, 309:C332-C347.
54. Limou S., et al. APOL1 toxin, innate immunity, and kidney injury. Kidney Int. 2015, 88:28-34.
55. Ito K., et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ. Res. 2014, 114:845-850.
56. Mukamal K.J., et al. APOL1 genotype, kidney and cardiovascular disease, and death in older adults. Arterioscler. Thromb. Vasc. Biol. 2015, 36:398-403.
57. Langefeld C.D., et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int. 2015, 87:169-175.
58. Bentley A.R., et al. Variation in APOL1 contributes to ancestry-level differences in HDLc-kidney function association. Int. J. Nephrol. 2012, 2012:748984.
59. Bentley A.R., et al. APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans. BMC Genomics 2015, 16:421.
60. Hartleben B., et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Invest. 2010, 120:1084-1096.
61. Bechtel W., et al. Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis. J. Am. Soc. Nephrol. 2013, 24:727-743.
62. Raper J., et al. Characterization of a novel trypanosome lytic factor from human serum. Infect Immun. 1999, 67:1910-1916.
63. Bullard W., et al. Haptoglobin-hemoglobin receptor independent killing of African trypanosomes by human serum and trypanosome lytic factors. Virulence 2012, 3:72-76.
64. Shiflett A.M., et al. Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J. Biol. Chem. 2005, 280:32578-32585.
65. Davidson W.S., et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 2009, 29:870-876.
66. Drain J., et al. Haptoglobin-related protein mediates trypanosome lytic factor binding to trypanosomes. J. Biol. Chem. 2001, 276:30254-30260.
67. Vanhollebeke B., et al. A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in humans. Science 2008, 320:677-681.
68. Stephens N.A., Hajduk S.L. Endosomal localization of the serum resistance-associated protein in African trypanosomes confers human infectivity. Eukaryot. Cell 2011, 10:1023-1033.
69. Styer A.L., Hajduk S.L. Trypanosome lytic factor-1 initiates oxidation-stimulated osmotic lysis of Trypanosoma brucei brucei. J. Biol. Chem. 2015, 291:3063-3075.
70. Allison A.C. The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertian malaria. Trans. R. Soc. Trop. Med. Hyg. 1954, 48:312-318.
71. Hedrick P.W. Population genetics of malaria resistance in humans. Heredity (Edinb.) 2011, 107:283-304.
72. Lopez C., et al. Mechanisms of genetically-based resistance to malaria. Gene 2010, 467:1-12.
73. Xong H.V., et al. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell 1998, 95:839-846.
74. Uzureau P., et al. Mechanism of Trypanosoma brucei gambiense resistance to human serum. Nature 2013, 501:430-434.
75. Samanovic M., et al. Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection. PLoS Pathog. 2009, 5:e1000276.
76. Taylor H.E., et al. The innate immune factor apolipoprotein L1 restricts HIV-1 infection. J. Virol. 2014, 88:592-603.
77. McLaren P.J., et al. Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. Retrovirology 2015, 12:41.
78. Tanawattanacharoen S., et al. Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am. J. Kidney Dis. 2000, 35:1166-1174.
79. Moudgil A., et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int. 2001, 59:2126-2133.
80. Divers J., et al. JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int. 2013, 84:1207-1213.
81. Ulasi I.I., et al. High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria. Nephron Clin. Pract. 2013, 123:123-128.
82. Foster M.C., et al. APOL1 variants associate with increased risk of CKD among African Americans. J. Am. Soc. Nephrol. 2013, 24:1484-1491.